These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 8598621)

  • 1. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group.
    Israel E; Cohn J; Dubé L; Drazen JM
    JAMA; 1996 Mar; 275(12):931-6. PubMed ID: 8598621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group.
    Liu MC; Dubé LM; Lancaster J
    J Allergy Clin Immunol; 1996 Nov; 98(5 Pt 1):859-71. PubMed ID: 8939149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group.
    DuBuske LM; Grossman J; Dubé LM; Swanson LJ; Lancaster JF
    Am J Manag Care; 1997 Apr; 3(4):633-40. PubMed ID: 10169531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled study.
    Wenzel S; Busse W; Calhoun W; Panettieri R; Peters-Golden M; Dube L; Walton-Bowen K; Russell H; Harris J
    J Asthma; 2007 May; 44(4):305-10. PubMed ID: 17530530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics.
    Dahlén B; Nizankowska E; Szczeklik A; Zetterström O; Bochenek G; Kumlin M; Mastalerz L; Pinis G; Swanson LJ; Boodhoo TI; Wright S; Dubé LM; Dahlén SE
    Am J Respir Crit Care Med; 1998 Apr; 157(4 Pt 1):1187-94. PubMed ID: 9563738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma.
    Israel E; Rubin P; Kemp JP; Grossman J; Pierson W; Siegel SC; Tinkelman D; Murray JJ; Busse W; Segal AT; Fish J; Kaiser HB; Ledford D; Wenzel S; Rosenthal R; Cohn J; Lanni C; Pearlman H; Karahalios P; Drazen JM
    Ann Intern Med; 1993 Dec; 119(11):1059-66. PubMed ID: 8239223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled trial comparing zileuton with theophylline in moderate asthma. The Zileuton Study Group.
    Schwartz HJ; Petty T; Dubé LM; Swanson LJ; Lancaster JF
    Arch Intern Med; 1998 Jan; 158(2):141-8. PubMed ID: 9448552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study.
    Nelson H; Kemp J; Berger W; Corren J; Casale T; Dube L; Walton-Bowen K; LaVallee N; Stepanians M
    Ann Allergy Asthma Immunol; 2007 Aug; 99(2):178-84. PubMed ID: 17718106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and clinical efficacy of zileuton in patients with chronic asthma.
    Lazarus SC; Lee T; Kemp JP; Wenzel S; Dubé LM; Ochs RF; Carpentier PJ; Lancaster JF
    Am J Manag Care; 1998 Jun; 4(6):841-8. PubMed ID: 10181070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma.
    Watkins PB; Dube LM; Walton-Bowen K; Cameron CM; Kasten LE
    Drug Saf; 2007; 30(9):805-15. PubMed ID: 17722971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma.
    O'Connor BJ; Löfdahl CG; Balter M; Szczeklik A; Boulet LP; Cairns CB
    Respir Med; 2007 Jun; 101(6):1088-96. PubMed ID: 17360171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of chronic stable asthma with drugs active on the 5-lipoxygenase pathway.
    Drazen JM; Israel E
    Int Arch Allergy Immunol; 1995; 107(1-3):319-20. PubMed ID: 7613158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization.
    Woodruff PG; Albert RK; Bailey WC; Casaburi R; Connett JE; Cooper JA; Criner GJ; Curtis JL; Dransfield MT; Han MK; Harnden SM; Kim V; Marchetti N; Martinez FJ; McEvoy CE; Niewoehner DE; Reilly JJ; Rice K; Scanlon PD; Scharf SM; Sciurba FC; Washko GR; Lazarus SC;
    COPD; 2011 Feb; 8(1):21-9. PubMed ID: 21299475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin.
    Israel E; Fischer AR; Rosenberg MA; Lilly CM; Callery JC; Shapiro J; Cohn J; Rubin P; Drazen JM
    Am Rev Respir Dis; 1993 Dec; 148(6 Pt 1):1447-51. PubMed ID: 8256883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of a 5-lipoxygenase inhibitor on acute mountain sickness and urinary leukotriene e4 after ascent to high altitude.
    Grissom CK; Richer LD; Elstad MR
    Chest; 2005 Feb; 127(2):565-70. PubMed ID: 15705997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor.
    Meltzer SS; Hasday JD; Cohn J; Bleecker ER
    Am J Respir Crit Care Med; 1996 Mar; 153(3):931-5. PubMed ID: 8630575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of single-dose zileuton on bronchial hyperresponsiveness in asthmatic patients treated with inhaled corticosteroids.
    Dekhuijzen PN; Bootsma GP; Wielders PL; van den Berg LR; Festen J; van Herwaarden CL
    Eur Respir J; 1997 Dec; 10(12):2749-53. PubMed ID: 9493655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, comparative, multicentric clinical trial to assess the efficacy and safety of zileuton extended-release tablets with montelukast sodium tablets in patients suffering from chronic persistent asthma.
    Kubavat AH; Khippal N; Tak S; Rijhwani P; Bhargava S; Patel T; Shah N; Kshatriya RR; Mittal R
    Am J Ther; 2013; 20(2):154-62. PubMed ID: 22926233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
    D'Alonzo GE; Nathan RA; Henochowicz S; Morris RJ; Ratner P; Rennard SI
    JAMA; 1994 May; 271(18):1412-6. PubMed ID: 7909853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis.
    Weinblatt ME; Kremer JM; Coblyn JS; Helfgott S; Maier AL; Petrillo G; Henson B; Rubin P; Sperling R
    J Rheumatol; 1992 Oct; 19(10):1537-41. PubMed ID: 1334515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.